Lancet
Department of Allergy and Allied Respiratory Disorders, Guy's Hospital, London, UK.
Published: August 1990
In a randomised, double-blind, crossover study, single oral doses of cromakalim, a potassium-channel activator, or placebo were given to 23 patients with nocturnal asthma. There was a significant reduction (p less than 0.005) in the early morning fall in forced expiratory volume in 1 s (FEV1) after 0.5 mg cromakalim (fall 9.8% [SEM 3.2%]) compared with placebo (18.5 [2.8]%). In a repeat dosing study, administration of 0.25 mg and 0.5 mg cromakalim on 5 consecutive nights to a further group of 8 asthmatic subjects significantly reduced the early morning fall in FEV1 from 28.7 (6.5)% after placebo to 19 (4.2)% after 0.25 mg and 14.9 (6.5)% after 0.5 mg. Potassium-channel activators may be useful in the treatment of asthma, especially for nocturnal symptoms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0140-6736(90)91877-d | DOI Listing |
Sleep Health
January 2025
Bradley-Hasbro Children's Research Center, Hasbro Children's Hospital, Providence, Rhode Island, USA; Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA; Department of Pediatrics, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Objectives: Children with asthma living in urban environments are at risk for disrupted sleep due to the presence of nocturnal asthma symptoms and urban stressors. Suboptimal sleep can affect children's daily functioning. The current study examined the effects of experimental sleep disruption on daytime performance in children with persistent asthma from urban backgrounds.
View Article and Find Full Text PDFJ Allergy Clin Immunol
January 2025
Department of Public Health Sciences, Henry Ford Health, Detroit, MI; Center for Bioinformatics, Henry Ford Health, Detroit, MI. Electronic address:
Background: Nocturnal cough affects approximately 1 in 3 children, can negatively impact child health, and is often attributable to asthma. The association of the gut microbiome with nocturnal cough has not been investigated.
Objective: To investigate the association between early-life gut microbiome composition and nocturnal cough overall and in the context of asthma.
Zhonghua Yi Xue Za Zhi
January 2025
Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou510515, China.
To investigate the characteristics of type 2 inflammation in patients with nocturnal asthma, and analyze the improvement of asthma symptoms after the use of inhaled corticosteroids (ICS) combined with different long-acting bronchodilators. Data of 231 asthma patients who first visited the Respiratory and Critical Care Medical Clinic of Nanfang Hospital of Southern Medical University from January 2020 to June 2023 and had positive bronchodilator tests (BDT), were retrospectively analyzed. These patients were divided into nocturnal asthma group and non-nocturnal asthma group based on the presence or absence of nocturnal symptoms.
View Article and Find Full Text PDFPolymers (Basel)
December 2024
Department of Zoology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.
Nocturnal asthma (NA) is a high-prevalence disease that causes severe respiratory issues, leading to death from early midnight to early morning. In this research, nanoparticulate drug delivery system of methylprednisolone (MP) was developed using chitosan (CH) and pectin (PEC). MP is a synthetic corticosteroid medication widely used for its potent anti-inflammatory activity.
View Article and Find Full Text PDFThorax
January 2025
Department of Pulmonology and Home Mechanical Ventilation, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Purpose: In patients with chronic obstructive pulmonary disease (COPD) treated with chronic non-invasive ventilation (NIV), the relation between improvements in nocturnal transcutaneous partial pressure of CO (PtcCO) and daytime arterial partial pressure of CO (PaCO) remains uncertain. Also, to what extent improvements in nocturnal PtcCO result in better health-related quality of life (HRQL), exercise capacity, lung function and survival has not been investigated.
Patients And Methods: Patients with COPD who were initiated on chronic NIV were prospectively followed for 6 months.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.